[HTML][HTML] Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
…, M Yaugel-Novoa, S Denolly, B Boson, T Bourlet, A Bal… - Nature, 2021 - nature.com
Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine 1 , 2 ,
European health authorities recommended that patients under the age of 55 years who …
European health authorities recommended that patients under the age of 55 years who …
[PDF][PDF] Type I IFN immunoprofiling in COVID-19 patients
…, M Bouscambert, V Escuret, E Frobert, A Bal… - Journal of Allergy and …, 2020 - Elsevier
Funding-Quanterix provided the kits for this study free of charge. 37 Conflict of interest–Pons
S, Oriol G, Brengel-Pesce K, Mouton W, Compagnon C are Biomérieux® 38 employeers. …
S, Oriol G, Brengel-Pesce K, Mouton W, Compagnon C are Biomérieux® 38 employeers. …
[HTML][HTML] Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69–V70, France, August to …
We report the strategy leading to the first detection of variant of concern 202012/01 (VOC) in
France (21 December 2020). First, the spike (S) deletion H69–V70 (ΔH69/ΔV70), identified …
France (21 December 2020). First, the spike (S) deletion H69–V70 (ΔH69/ΔV70), identified …
[HTML][HTML] Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
…, T Julien, S Paul, P Bastard, A Belot, A Bal… - Journal of Experimental …, 2021 - rupress.org
IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3–…
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3–…
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
…, M Neuville, B Neven, S Keles, R Hernu, A Bal… - Science …, 2023 - science.org
Life-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning
antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting …
antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting …
Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation
…, C Scholtes, F Morfin, M Valette, B Lina, A Bal… - Virus …, 2020 - academic.oup.com
Since the beginning of the COVID-19 outbreak, SARS-CoV-2 whole-genome sequencing (WGS)
has been performed at unprecedented rate worldwide with the use of very diverse Next-…
has been performed at unprecedented rate worldwide with the use of very diverse Next-…
[HTML][HTML] Tracking the international spread of SARS-CoV-2 lineages B. 1.1. 7 and B. 1.351/501Y-V2 with grinch
…, CK Lim, M Chironna, D Loconsole, A Bal… - Wellcome Open …, 2021 - ncbi.nlm.nih.gov
Late in 2020, two genetically-distinct clusters of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) with mutations of biological concern were reported, one in the United …
2 (SARS-CoV-2) with mutations of biological concern were reported, one in the United …
[HTML][HTML] Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation in France
A Bal, B Simon, G Destras, R Chalvignac… - Nature …, 2022 - nature.com
From December 2021-February 2022, an intense and unprecedented co-circulation of
SARS-CoV-2 variants with high genetic diversity raised the question of possible co-infections …
SARS-CoV-2 variants with high genetic diversity raised the question of possible co-infections …
[HTML][HTML] Performance assessment of SARS-CoV-2 PCR assays developed by WHO referral laboratories
S Etievant, A Bal, V Escuret, K Brengel-Pesce… - Journal of clinical …, 2020 - mdpi.com
A reliable diagnostic assay is crucial to early detect new COVID-19 cases and limit severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. Since the onset of the …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. Since the onset of the …
[HTML][HTML] Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y. V1 (B. 1.1. 7, variant of concern 202012/01) in France, January to …
…, S Burrel, S Behillil, C Sauvage, A Bal… - …, 2021 - eurosurveillance.org
The emergence of SARS-CoV-2 variant 20I/501Y.V1 (VOC-202012/1 or GR/501Y.V1) is
concerning given its increased transmissibility. We reanalysed 11,916 PCR-positive tests (41% …
concerning given its increased transmissibility. We reanalysed 11,916 PCR-positive tests (41% …